Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinpoint Trials

Neither a doctor nor a teaching hospital

Research payments

$105,139

42 payments

Through program year 2025, Clinpoint Trials is reported as receiving $105,139 in research payments, across 42 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $5,591 7
2024 Research $4,974 5
2023 Research $7,450 15
2022 Research $13,506 10
2021 Research $19,365 1
2019 Research $54,254 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $54,254 4 payments
  2. AbbVie, Inc. $27,569 30 payments
  3. AstraZeneca UK Limited $19,365 1 payment
  4. AstraZeneca Pharmaceuticals LP $3,542 1 payment
  5. Teva Pharmaceuticals USA, Inc. $409 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A 28-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Grou $54,254 4 payments
  2. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 $22,907 2 payments
  3. Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C $4,882 6 payments
  4. Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants $4,602 3 payments
  5. Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) $2,334 2 payments
  6. A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment Extension $2,192 3 payments
  7. Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine $1,537 2 payments
  8. 3110-305-002 Ph3 Pivotal Peds Post Approval - PMR (M21-265) $1,440 1 payment
  9. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) $1,440 1 payment
  10. LIN-MD-64 Ph3 Ped FC and IBS-C Trial 6-17 (M21-567) $1,080 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record